Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

GOSERELIN ACETATE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (L02A, L02AE) — coverage varies; not interchangeable

  • Buserelin (Suprefact Depot 2 Months): general benefit
  • Leuprolide (Lupron Depot PDS): general benefit
  • Triptorelin (Trelstar (1 Month)): general benefit
  • Megestrol (Megace): general benefit, Not a benefit

Zoladex · DIN 02049325 · 3.6mg · Depot injection

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Zoladex · DIN 02049325 Manufacturer: TerSera Therapeutics LLC; listing date 1996-10-01 Health Canada: Marketed since 2018-02-28 · brand ZOLADEX · ATC L02AE03 GOSERELIN · form Implant · route Subcutaneous · ingredients GOSERELIN (GOSERELIN ACETATE) 3.6 MG · company Tersera therapeutics llc · schedule Prescription
Check this DIN again · Health Canada product record

Zoladex: Formulary list price $422.6778/unit (unit not stated in source; not the patient's cost)

Ministry pays: $422.6778 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16216 · Verify on the e-Formulary ↗ (DIN 02049325)

Source record
DIN 02049325: Zoladex Raw flags: sec3=Y Item: 100000069; group id 166; item number 0281; lccId None; manufacturer id TRS Source form: Depot Inj; strength: 3.6mg Recorded listing: General benefit Source prices (unrounded): $422.6778; ministry $422.6778 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02049325 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16216
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02049325
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zoladex LA · DIN 02225905 · 10.8mg · Depot injection

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Zoladex LA · DIN 02225905 Manufacturer: TerSera Therapeutics LLC; listing date 1996-12-19 Health Canada: Marketed since 2018-02-28 · brand ZOLADEX LA · ATC L02AE03 GOSERELIN · form Implant · route Subcutaneous · ingredients GOSERELIN (GOSERELIN ACETATE) 10.8 MG · company Tersera therapeutics llc · schedule Prescription
Check this DIN again · Health Canada product record

Zoladex LA: Formulary list price $1204.7322/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1204.7322 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43433 · Verify on the e-Formulary ↗ (DIN 02225905)

Source record
DIN 02225905: Zoladex LA Raw flags: sec3=Y Item: 100000110; group id 166; item number 0282; lccId None; manufacturer id TRS Source form: Depot Inj; strength: 10.8mg Recorded listing: General benefit Source prices (unrounded): $1204.7322; ministry $1204.7322 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02225905 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43433
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02225905
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

LEUPROLIDE ACETATE

· 11 products · General benefit · strengths: 3.75mg, 7.5mg, 11.25mg, 22.5mg, 30mg, 3.75mg/Vial, 22.5mg/Vial, 45mg · Inj-Kit, Pd for Inj - Vial Pk, Pd Susp Inj-Pref Syr Kit

TRIPTORELIN PAMOATE

· 5 products · General benefit · strengths: 3.75mg/Vial, 11.25mg/Vial, 22.5mg/Vial · Inj Pd with Sterile Water-Vial Pk, Inj Pd-Vial Pk, SR Inj Pd with Sterile Water-Vial Pk

MEGESTROL ACETATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 40mg, 160mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: endometriosis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: LEUPROLIDE ACETATE LEUPROLIDE ACETATE · General benefit LUPRON DEPOT (leuprolide acetate) Page 5 of 97 Unclassified / Non classifié Endometriosis LUPRON DEPOT 3.75 mg (1-Month) and 11.25 mg (3-Month) are indicated for: • the treatment of endometriosis, including pain relief and reduction of endometriosis lesions, for a period of six months. PM: https://pdf.hres.ca/dpd_pm/00082398.PDF; date 2025-11-13; DIN 00836273; fetched 2026-09-10 Product monograph • the treatment of endometriosis, including pain relief and reduction of endometriosis lesions, for a period of six months. LUPRON DEPOT with norethindrone acetate 5 mg daily is indicated for the initial management of endometriosis and for management of recurrence of symptoms. PM: https://pdf.hres.ca/dpd_pm/00082398.PDF; date 2025-11-13; DIN 00836273; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE ZOLADEX® (goserelin acetate) is indicated for a number of hormone-dependent conditions as shown below under the headings Prostate Cancer, Breast Cancer and Benign Conditions: Prostate Cancer  ZOLADEX is indicated for the palliative treatment of patients with hormone- dependent advanced carcinoma of the prostate (Stage M1 according to the Tumour- Node-Metastasis [TNM] classification system or Stage D2 according to the American Urologic Association [AUA] classification).  ZOLADEX is indicated for use in combination with a non-steroidal antiandrogen and radiation therapy for the management of locally advanced (T3, T4) or bulky Stage T2b, T2c carcinoma of the prostate. Treatment with ZOLADEX and a non- steroidal antiandrogen should start 8 weeks prior to initiating radiation therapy and continue until completion of the radiation therapy.  ZOLADEX as adjuvant hormone therapy to external beam irradiation for patients with locally advanced prostate cancer (Stage T3-T4). Breast Cancer  ZOLADEX is indicated as an alternative to standard adjuvan… https://pdf.hres.ca/dpd_pm/00042728.PDF PM date: December 21, 2017 Source product: ZOLADEX; DIN 02049325; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.